Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma

Alessandra Romano, Marco Santoro, Concetta Conticello, Sergio Siragusa, Francesco DI Raimondo, Giovanni Martinelli, Claudio Cerchione

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalPanminerva Medica
Volume63
Issue number1
DOIs
Publication statusPublished - Mar 2021

Fingerprint Dive into the research topics of 'Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma'. Together they form a unique fingerprint.

Cite this